Veru, Inc. (VERU) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162442,
    "name": "Veru, Inc.",
    "stock_name": "Veru, Inc.",
    "full_name": "Veru, Inc.",
    "name_url": "stocks-analysis/veru-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.42",
    "chg": 0.06,
    "chgp": "2.54%",
    "dir": 1,
    "prev_price": "2.36",
    "mcapval": "56.76",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US92536C1036",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "167.64 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/veru-inc-1162442-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Veru, Inc. Hits 52-Week Low at $2.11 Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veru-inc-hits-52-week-low-at-211-amid-market-volatility-3721497",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeruInc_priceRelatedfactors_3721497.png",
        "date": "2025-11-21 15:45:01",
        "description": "Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. Despite a strong one-year performance, the company faces significant financial difficulties, including negative return on equity and a high price-to-book ratio, alongside declining operating profits and a modest market capitalization."
      },
      {
        "title": "Veru, Inc. Hits New 52-Week Low at $2.34 Amid Ongoing Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veru-inc-hits-new-52-week-low-at-234-amid-ongoing-challenges-3718608",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeruInc_priceRelatedfactors_3718608.png",
        "date": "2025-11-20 16:26:19",
        "description": "Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges despite a significant one-year performance increase. The company faces financial strain with negative return on equity and a declining operating profit. Its current market cap is USD 57 million, highlighting its microcap status in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Veru, Inc. Hits 52-Week Low at $2.42 Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veru-inc-hits-52-week-low-at-242-amid-market-challenges-3686410",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeruInc_priceRelatedfactors_3686410.png",
        "date": "2025-11-10 17:04:59",
        "description": "Veru, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting ongoing market challenges despite a strong one-year performance. The company faces financial difficulties, including negative return on equity and a declining long-term growth outlook, necessitating a strategic reassessment."
      },
      {
        "title": "Veru, Inc. Stock Hits 52-Week Low at $2.46 Amid Financial Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veru-inc-stock-hits-52-week-low-at-246-amid-financial-struggles-3673985",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeruInc_priceRelatedfactors_3673985.png",
        "date": "2025-11-05 16:29:31",
        "description": "Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. Despite a strong one-year performance, the company faces significant volatility and financial difficulties, including negative return on equity and a high price-to-book ratio, raising concerns about its long-term growth prospects."
      },
      {
        "title": "Veru, Inc. Stock Hits 52-Week Low at USD 2.53 Amid Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veru-inc-stock-hits-52-week-low-at-usd-253-amid-challenges-3671460",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeruInc_priceRelatedfactors_3671460.png",
        "date": "2025-11-04 17:45:50",
        "description": "Veru, Inc., a microcap pharmaceutical company, has reached a new 52-week low, reflecting ongoing challenges in a competitive market despite a strong one-year performance. With a market cap of USD 57 million, the company faces financial difficulties, including negative return on equity and declining operating profit growth."
      },
      {
        "title": "Is Veru, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-veru-inc-technically-bullish-or-bearish-3545160",
        "imagepath": "",
        "date": "2025-09-20 19:05:02",
        "description": "As of 8 September 2025, the technical trend for Veru, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Bollinger Bands are mildly bearish on both weekly and monthly time frames. Daily moving averages are bearish, and both KST and Dow Theory show no trend on the weekly and monthly charts. \n\nIn terms of performance, Veru has underperformed the S&P 500 across multiple periods, with a year-to-date return of -45.12% compared to the S&P 500's 12.22%, and a one-year return of -53.64% versus the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but the strength is tempered by bearish indicators in the weekly MACD and moving averages...."
      },
      {
        "title": "Is Veru, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-veru-inc-overvalued-or-undervalued-3541879",
        "imagepath": "",
        "date": "2025-09-20 17:38:36",
        "description": "As of 9 February 2022, the valuation grade for Veru, Inc. has moved from fair to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued given its substantial negative performance metrics, including a Price to Book Value of 4.37, an EV to EBIT of -1.84, and an EV to EBITDA of -1.85. Comparatively, peers like G1 Therapeutics, Inc. and ADC Therapeutics SA show even worse EV to EBITDA ratios of -9.6487 and -4.7475, respectively, but Veru's metrics still suggest a concerning valuation.\n\nThe stock has underperformed significantly against the S&P 500, with a year-to-date return of -45.12% compared to the index's 12.22%. This trend continues over longer periods, with a 3-year return of -97.50% versus the S&P's 70.41%. Overall, the combination of poor financial ratios and substantial negative returns indicates that Veru, Inc. is overvalued in the current market c..."
      }
    ],
    "total": 12,
    "sid": "1162442",
    "stock_news_url": "https://www.marketsmojo.com/news/veru-inc-1162442"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Veru, Inc. Hits 52-Week Low at $2.11 Amid Market Volatility

2025-11-21 15:45:01

Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. Despite a strong one-year performance, the company faces significant financial difficulties, including negative return on equity and a high price-to-book ratio, alongside declining operating profits and a modest market capitalization.

Veru, Inc. Hits New 52-Week Low at $2.34 Amid Ongoing Challenges

2025-11-20 16:26:19

Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges despite a significant one-year performance increase. The company faces financial strain with negative return on equity and a declining operating profit. Its current market cap is USD 57 million, highlighting its microcap status in the Pharmaceuticals & Biotechnology sector.

Veru, Inc. Hits 52-Week Low at $2.42 Amid Market Challenges

2025-11-10 17:04:59

Veru, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting ongoing market challenges despite a strong one-year performance. The company faces financial difficulties, including negative return on equity and a declining long-term growth outlook, necessitating a strategic reassessment.

Veru, Inc. Stock Hits 52-Week Low at $2.46 Amid Financial Struggles

2025-11-05 16:29:31

Veru, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. Despite a strong one-year performance, the company faces significant volatility and financial difficulties, including negative return on equity and a high price-to-book ratio, raising concerns about its long-term growth prospects.

Veru, Inc. Stock Hits 52-Week Low at USD 2.53 Amid Challenges

2025-11-04 17:45:50

Veru, Inc., a microcap pharmaceutical company, has reached a new 52-week low, reflecting ongoing challenges in a competitive market despite a strong one-year performance. With a market cap of USD 57 million, the company faces financial difficulties, including negative return on equity and declining operating profit growth.

Is Veru, Inc. technically bullish or bearish?

2025-09-20 19:05:02

As of 8 September 2025, the technical trend for Veru, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Bollinger Bands are mildly bearish on both weekly and monthly time frames. Daily moving averages are bearish, and both KST and Dow Theory show no trend on the weekly and monthly charts. In terms of performance, Veru has underperformed the S&P 500 across multiple periods, with a year-to-date return of -45.12% compared to the S&P 500's 12.22%, and a one-year return of -53.64% versus the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but the strength is tempered by bearish indicators in the weekly MACD and moving averages....

Is Veru, Inc. overvalued or undervalued?

2025-09-20 17:38:36

As of 9 February 2022, the valuation grade for Veru, Inc. has moved from fair to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued given its substantial negative performance metrics, including a Price to Book Value of 4.37, an EV to EBIT of -1.84, and an EV to EBITDA of -1.85. Comparatively, peers like G1 Therapeutics, Inc. and ADC Therapeutics SA show even worse EV to EBITDA ratios of -9.6487 and -4.7475, respectively, but Veru's metrics still suggest a concerning valuation. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -45.12% compared to the index's 12.22%. This trend continues over longer periods, with a 3-year return of -97.50% versus the S&P's 70.41%. Overall, the combination of poor financial ratios and substantial negative returns indicates that Veru, Inc. is overvalued in the current market c...

View All News